{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:49:29Z","timestamp":1794242969155,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2025JJ80494"],"award-info":[{"award-number":["2025JJ80494"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01569-w","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T12:32:24Z","timestamp":1753533144000},"page":"836-843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical features, treatment and outcomes of dabrafenib-associated uveitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Jieqiong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"issue":"12","key":"1569_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s40265-013-0095-2","volume":"73","author":"AD Ballantyne","year":"2013","unstructured":"Ballantyne AD, Garnock-Jones KP (2013) Dabrafenib: first global approval. Drugs 73(12):1367\u20131376. https:\/\/doi.org\/10.1007\/s40265-013-0095-2","journal-title":"Drugs"},{"issue":"7","key":"1569_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E et al (2019) Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 381(7):626\u2013636. https:\/\/doi.org\/10.1056\/NEJMoa1904059","journal-title":"N Engl J Med"},{"issue":"19","key":"1569_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V et al (2017) Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 377(19):1813\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1708539","journal-title":"N Engl J Med"},{"issue":"9839","key":"1569_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358\u2013365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"issue":"2","key":"1569_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2478\/raon-2018-0002","volume":"52","author":"AU Gavric","year":"2018","unstructured":"Gavric AU, Ocvirk J, Mekjavic PJ (2018) Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib. Radiol Oncol 52(2):213\u2013219. https:\/\/doi.org\/10.2478\/raon-2018-0002","journal-title":"Radiol Oncol"},{"issue":"2","key":"1569_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s0002-9394(14)74235-7","volume":"103","author":"E Bloch-Michel","year":"1987","unstructured":"Bloch-Michel E, Nussenblatt RB (1987) International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2):234\u2013235. https:\/\/doi.org\/10.1016\/s0002-9394(14)74235-7","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1569_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/s0002-9394(01)00925-4","volume":"131","author":"RW Read","year":"2001","unstructured":"Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L et al (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647\u2013652. https:\/\/doi.org\/10.1016\/s0002-9394(01)00925-4","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"1569_CR8","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","volume":"128","author":"C Mettler","year":"2021","unstructured":"Mettler C, Monnet D, Kramkimel N, Tr\u00e9luyer JM, Mouthon L, Br\u00e9zin A et al (2021) Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database. Ophthalmology 128(12):1748\u20131755. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.008","journal-title":"Ophthalmology"},{"key":"1569_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2020.11.027","volume":"144","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou F, Urner-Bloch U, Eggenschwiler C, Mitsakakis N, Mangana J, Dummer R, Urner M (2021) The association between immune checkpoint or BRAF\/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer 144:215\u2013223. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.027","journal-title":"Eur J Cancer"},{"issue":"2","key":"1569_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1159\/000511340","volume":"12","author":"M Chang","year":"2021","unstructured":"Chang M, Kuriakose RK, Xu K, Almeida DRP, Chin EK (2021) Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma. Case Rep Ophthalmol 12(2):574\u2013577. https:\/\/doi.org\/10.1159\/000511340","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"1569_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000357060","volume":"4","author":"L Joshi","year":"2013","unstructured":"Joshi L, Karydis A, Gemenetzi M, Shao EH, Taylor SR (2013) Uveitis as a Result of MAP Kinase Pathway Inhibition. Case Rep Ophthalmol 4(3):279\u2013282. https:\/\/doi.org\/10.1159\/000357060","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"1569_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/IIO.0000000000000072","volume":"55","author":"IY Yeung","year":"2015","unstructured":"Yeung IY, Popp NA, Chan CC (2015) The role of sex in uveitis and ocular inflammation. Int Ophthalmol Clin 55(3):111\u2013131. https:\/\/doi.org\/10.1097\/IIO.0000000000000072","journal-title":"Int Ophthalmol Clin"},{"issue":"8","key":"1569_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3928\/23258160-20230524-01","volume":"54","author":"NZ Kaymak","year":"2023","unstructured":"Kaymak NZ, Kaplan AT (2023) Vogt-Kayanagi-Harada-Like Uveitis Induced by Dabrafenib\/Trametinib Therapy for Cutaneous Malignant Melanoma. Ophthalmic Surg Lasers Imaging Retina 54(8):477\u2013480. https:\/\/doi.org\/10.3928\/23258160-20230524-01","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"1569_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579523","volume":"11","author":"A Boutros","year":"2020","unstructured":"Boutros A, Schiavi C, Cecchi F, Spagnolo F, Guadagno A, Tanda ET et al (2020) Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient. Front Immunol 11:579523. https:\/\/doi.org\/10.3389\/fimmu.2020.579523","journal-title":"Front Immunol"},{"issue":"10","key":"1569_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.oftal.2020.05.014","volume":"95","author":"R Campos Polo","year":"2020","unstructured":"Campos Polo R, Garc\u00edaGuisado D, Rubio S\u00e1nchez C, M\u00e1rquezIvacevich NT (2020) Usefulness of intravitreal dexamethasone implant in the management of \u00abVogt-Koyanagi-Harada-like syndrome\u00bb secondary to map kinase pathway inhibition. Arch Soc Esp Oftalmol (Engl Ed) 95(10):501\u2013506. https:\/\/doi.org\/10.1016\/j.oftal.2020.05.014","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"1569_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.2147\/OTT.S72951","volume":"8","author":"I Lugowska","year":"2015","unstructured":"Lugowska I, Kose\u0142a-Paterczyk H, Kozak K, Rutkowski P (2015) Trametinib: a MEK inhibitor for management of metastatic melanoma. Onco Targets Ther 8:2251\u20132259. https:\/\/doi.org\/10.2147\/OTT.S72951","journal-title":"Onco Targets Ther"},{"issue":"8","key":"1569_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","volume":"13","author":"GS Falchook","year":"2012","unstructured":"Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ et al (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13(8):782\u2013789. https:\/\/doi.org\/10.1016\/S1470-2045(12)70269-3","journal-title":"Lancet Oncol"},{"issue":"7","key":"1569_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/imt-2019-0206","volume":"12","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Seifert C, Lehmann M, Lukas C, Scheel C, Susok L (2020) Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 12(7):439\u2013444. https:\/\/doi.org\/10.2217\/imt-2019-0206","journal-title":"Immunotherapy"},{"issue":"6","key":"1569_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, Tanita K, Sato Y, Hidaka T, Otsuka A et al (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J Dermatol 45(6):735\u2013737. https:\/\/doi.org\/10.1111\/1346-8138.14273","journal-title":"J Dermatol"},{"issue":"4","key":"1569_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ajo.2014.07.003","volume":"158","author":"CH Choe","year":"2014","unstructured":"Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK (2014) Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 158(4):831-837.e2. https:\/\/doi.org\/10.1016\/j.ajo.2014.07.003","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1569_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/med4.14","volume":"1","author":"Q Wu","year":"2023","unstructured":"Wu Q, Niu Y, Chen D, Lin H, Tan M, Hu Y et al (2023) Optical coherence tomography angiography features of retinal artery occlusion before and after intra-arterial thrombolysis. Med Adv 1(2):115\u2013122. https:\/\/doi.org\/10.1002\/med4.14","journal-title":"Med Adv"},{"issue":"11","key":"1569_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.annder.2019.08.012","volume":"146","author":"E Rohmer","year":"2019","unstructured":"Rohmer E, Scrivener JN, Schissler C, Cribier B, Lenormand C (2019) Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors. Ann Dermatol Venereol 146(11):725\u2013729. https:\/\/doi.org\/10.1016\/j.annder.2019.08.012","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"1569_CR23","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF et al (2012) Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18(5):1386\u20131394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2479. (Epub 2011 Dec 12)","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1569_CR24","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMc1111672","volume":"365","author":"NM Rochet","year":"2011","unstructured":"Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439\u20132441. https:\/\/doi.org\/10.1056\/NEJMc1111672","journal-title":"N Engl J Med"},{"key":"1569_CR25","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/ICU.0000000000000809","volume":"32","author":"A Joye","year":"2021","unstructured":"Joye A, Suhler E (2021) Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 32:574\u2013582. https:\/\/doi.org\/10.1097\/ICU.0000000000000809","journal-title":"Curr Opin Ophthalmol"},{"key":"1569_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","volume":"38","author":"JN Crosson","year":"2015","unstructured":"Crosson JN, Laird PW, Debiec M, Bergstrom CS, Lawson DH, Yeh S (2015) Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 38:80\u201384. https:\/\/doi.org\/10.1097\/CJI.0000000000000066","journal-title":"J Immunother"},{"issue":"11","key":"1569_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.autrev.2013.01.004","volume":"12","author":"A Greco","year":"2013","unstructured":"Greco A, Fusconi M, Gallo A, Turchetta R, Marinelli C, Macri GF, De Virgilio A, de Vincentiis M (2013) Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 12(11):1033\u20131038. https:\/\/doi.org\/10.1016\/j.autrev.2013.01.004","journal-title":"Autoimmun Rev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01569-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01569-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:46Z","timestamp":1760195026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01569-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01569-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}